FDA Grants Accelerated Approval to First Plasmid DNA-Based Immunotherapy for Recurrent Respiratory Papillomatosis

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) by Inovio Pharmaceuticals. This marks the first U.S. approval of a plasmid DNA-based immunotherapy, intended for adults with recurrent respiratory papillomatosis (RRP), a rare chronic disease caused by human papillomavirus (HPV). The therapy aims to reduce the frequency of surgical interventions for these patients.